结核分枝杆菌ICL mRNA特异性10-23脱氧核酶切割 活性的鉴定及其切割特点

为鉴定结核分枝杆菌异柠檬酸裂合梅(ICL)特异性的10-23DRz在无细胞体系切割ICL mRNA的活性,并探讨其在不同条件下以及联合应用时对靶mRNA的切割特点,采用计算机软件模拟ICL mRNA的二级结构,据此选择适合的待切割靶点并设计针对相应靶点的特异性10-23DRz（DZ1～DZ5）.PCR法扩增获得icl基因并克隆入质粒pET32a+.采用T7 RNA聚合酶体外转录法获取ICL全长mRNA后分别用DZ1～DZ5在无细胞体系中对ICL mRNA进行切割,切割产物经变性聚丙烯酰胺凝胺电泳后用银染法鉴定各DRzs的活性.选择切割活性最强的DZ4考察不同10-23DRz剂量、不同反应时间、不同镁离子浓度条件下及不同错配或突变10-23DRz的切割特点.联合应用DZ1、DZ4及DZ5在无细胞体系中对ICL mRNA进行切割,检测10-23DRz联合应用对切割效率的影响.结果表明,DZ1、DZ3、DZ4及DZ5可在无细胞体系中有效地切割ICL mRNA,其切割效率在30.8%～64.5%之间.对DZ4切割活性的检测发现,其对靶mRNA的切割具有剂量和时间的依赖性;在2～20 μmol/L范围内,DZ4的切割活性与Mg2＋浓度呈正相关;DZ4单侧底物结合臂上含一个不与靶mRNA配对的碱基时其切割效率大大降低,两侧底物结合臂上各含一个不配对的碱基或活性中心域第6位出现碱基突变（G→C）时,DZ4完全丧失切割活性.联合应用2种或2种以上10-23DRz可显著增强对底物RNA的切割效率.10-23 DRz特异、有效地切割结核分枝杆菌ICL全长mRNA并显示一定的叠加效应,有望用于抗结核分枝杆菌潜伏感染的基因治疗.     

人同源盒基因NKX3.1对前列腺癌细胞的诱导凋亡作用

构建人同源盒基因NKX3.1 cDNA真核表达载体,研究其在前列腺癌细胞PC-3、LNCaP 中的表达及对细胞的促凋亡作用.以人前列腺癌细胞LNCaP细胞中的总RNA为模板,RT-PCR扩增NKX3.1基因全长编码片段,将NKX3.1 cDNA重组到真核表达载体pcDNA3.1（+）中; 将pcDNA3.1-NKX3.1表达载体瞬时转染前列腺癌细胞PC-3和LNCaP 细胞,用RT-PCR和Western印迹检测NKX3.1 cDNA在转录水平和蛋白水平的表达;绘制细胞生长曲线,观察NKX3.1对前列腺癌细胞增殖的抑制作用;用DNA/ladder和流式细胞术检测NKX3.1对前列腺癌细胞凋亡的影响,进一步用RT PCR检测凋亡相关基因caspase3、caspase8、caspase9、Apaf1、survivin和Bcl2表达的变化.人同源盒基因NKX3.1 cDNA真核表达载体pcDNA3.1-NKX3.1经酶切及测序鉴定正确. pcDNA3.1-NKX3.1转染PC-3和LNCaP细胞后,经RT-PCR和Western印迹证明能有效表达NKX3.1.生长曲线显示,前列腺癌细胞转染NKX3.1 cDNA后细胞增殖受到抑制;前列腺癌细胞转染NKX3.1 cDNA 48 h后,DNA电泳呈现具有凋亡特征的DNA ladder;流式细胞术检测出现明显凋亡峰;RT-PCR检测凋亡相关基因.结果显示,caspase3、caspase8、caspase9基因表达明显增加,Bcl2基因表达明显减少.本研究成功构建了真核表达载体pcDNA3.1 NKX3.1, 转染PC3和LNCaP细胞后能有效表达,并对细胞具有诱导凋亡作用     

二级结构模拟辅助MTB脱氧核酶潜在作用靶点预测

异柠檬酸裂解酶(ICL)是结核病病原体结核分枝杆菌(MTB)乙醛酸循环中的关键酶,可作为抗结核新型药物治疗的潜在靶点。脱氧核酶(DRz)是一类独特的、具备酶活性的单链小分子DNA。实验针对MTBICL基因mRNA片段,通过二级结构模拟预测理论上适合与不适合DRz10～23作用的位点,据此设计针对ICL基因mRNA片段两种不同位点的DRz,并在体外水平上观察两种DRz对MTBICL基因mRNA片段的切割作用,以此验证底物二级结构模拟辅助MTB脱氧核酶潜在作用靶点预测的可行性。结果显示,底物二级结构模拟能够辅助预测MTB脱氧核酶潜在作用靶点,为探讨其作为抗结核病基因药物的可能提供实验基础。     

Screening of deoxyribozyme with high reversal efficiency against multidrug resistance in breast carcinoma cells

Specific inhibition of P-glycoprotein (Pgp) expression, which is encoded by multidrug resistance gene-1 (MDR1), is considered a well-respected strategy to overcome multidrug resistance (MDR). Deoxyribozymes (DRz) are catalytic nucleic acids that could cleave a target RNA in sequence-specific manner. However, it is difficult to select an effective target site for DRz in living cells. In this study, target sites of DRz were screened according to MDR1 mRNA secondary structure by RNA structure analysis software. Twelve target sites on the surface of MDR1 mRNA were selected. Accordingly, 12 DRzs were synthesized and their suppression effect on the MDR phenotype in breast cancer cells was confirmed. The results showed that 4 (DRz 2, 3, 4, 9) of the 12 DRzs could, in a dose-dependent response, significantly suppress MDR1 mRNA expression and restore chemosensitivity in breast cancer cells with MDR phenotype. This was especially true of DRz 3, which targets the 141 site purine-pyrimidine dinucleotide. Compared with antisense oligonucleotide or anti-miR-27a inhibitor, DRz 3 was more efficient in suppressing MDR1 mRNA and Pgp protein expression or inhibiting Pgp function. The chemosensitivity assay also proved DRz 3 to be the best one to reverse the MDR phenotype. The present study suggests that screening targets of DRzs according to MDR1 mRNA secondary structure could be a useful method to obtain workable ones. We provide evidence that DRzs (DRz 2, 3, 4, 9) are highly efficient at reversing the MDR phenotype in breast carcinoma cells and restoring chemosensitivity.     

反义CD151基因转染对大鼠血管平滑肌细胞迁移的影响

目的观察pcDNA3.1真核表达载体介导的反义CD151基因转染对培养的大鼠动脉平滑肌细胞(VSMCs)迁移的影响。方法构建携带全长正义和反义CD151的真核表达载体pcDNA3.1-CD151和pcDNA3.1-anti-CD151重组质粒,转染体外培养的VSMCs,以RT-PCR和Western blot方法检测CD151的表达,用Boyden趋化小室方法观察细胞迁移。结果与载体对照组、脂质体对照组和空白对照组3组均值比较,转染48h后,反义CD151组mRNA表达降低58%,蛋白表达降低51%,正义CD151组的VSMCs CD151mRNA表达增加171%,蛋白表达增加133%;趋化迁移的细胞数,反义CD151组为37.9±6.3,正义CD151组为86.5±12.4;载体对照组、脂质体对照组和空白对照组分别为60.3±7.1、61.8±7.6和67.3±9.6。反义CD151组显著低于其余各组(P<0.01),正义CD151组显著高于其余各组(P<0.01)。结论pcDNA3.1真核表达载体介导的反义CD151转染,通过抑制CD151的表达,能够显著抑制大鼠VSMCs的迁移。     

重组肾上腺髓质素表达载体的构建及在哺乳动物细胞中的表达

为探索通过体内表达肾上腺髓质素（adrenomedullin,AM）治疗高血压和慢性心衰的可能性,本实验构建了重组AM真核表达载体,并在无内源笥AM表达的K562细胞株上进行了体外表达实验。实验中采用RT－PCR技术扩增AM cDNA片段,并将扩增的cDNA片段插入pcDNA3.1真核表达质粒,构建成含AM cDNA的重组质料pcDNA3.1AM。用脂质体介导将该质粒转染培养的人白血病细腻K562株,在转染的细胞中,用RT－PCR检测证实有AM mRNA存在;用班点免疫分析方法检测转染细胞的培养液上清,证实有AM多肽存在,表明本实验中构建的重组pcDNA3.1AM载体能够在哺乳类细胞中表达AM。     

脱氧核酶的研究进展

具有RNA裂解活性的DNA分子称为脱氧核酶。它是经过体外选择技术经多次筛选获得的。脱氧核酶在切割与其互补的RNA底物分子时具有极高的特异性和切割效率,有望成为新的RNA灭活工具。     

脱氧核酶抑制Akt1基因对MCF-7乳腺癌细胞生长的影响

目的应用脱氧核酶抑制Akt1的表达,观察MCF-7乳腺癌细胞生长及凋亡情况。方法采用噻唑蓝比色法（MTT）检测脱氧核酶抑制MCF-7乳腺癌细胞增殖作用;DAPI染色法分析细胞凋亡形态学的变化;流式细胞术检测脱氧核酶对MCF-7乳腺癌细胞凋亡的影响;运用蛋白免疫印迹检测分析Akt1、pro—caspase-3、pro-caspase-9的变化。结果Aktl脱氧核酶对MCF-7乳腺癌细胞在体外的生长具有抑制作用;DRz1组的细胞早期凋亡率显著高于未处理组;荧光显微镜下可见典型的凋亡形态学变化;脱氧核酶作用后,免疫印迹检测Aktl蛋白表达降低,pro—caspase-3、9均被活化。结论AktlDRzl能有效下调MCF-7乳腺癌细胞Akt1的蛋白表达水平,抑制MCF-7细胞的生长,且凋亡途径可能依赖于caspase-3、9的相关的线粒体凋亡途径。     

抑制VEGF基因表达对大肠癌细胞HT-29的增殖影响

选择血管内皮生长因子（VEGF）基因为靶基因,设计两组针对VEGF mRNA的小干扰RNA．合成DNA寡核苷酸链,体外转录合成siRNA．以人大肠癌细胞系HT-29为靶细胞,应用脂质体转染的方法,将siRNA导入细胞．MTT法检测siRNA对细胞增殖率的影响,RT—PCR法比较转染前后VEGFmRNA表达水平的变化．ELISA法检测细胞培养液中VEGF蛋白分泌量的变化．结果表明,两组siRNA转染后均能有效地抑制HT-29细胞的生长,VEGF mRNA的表达量大幅度减少;相对应的VEGF蛋白水平也显著降低,而作为阴性对照的错义序列组siRNA转染后则无上述作用．     

基因药物研究现状和对策

生物技术药物以人类体细胞的基因组、转录本组和蛋白质组三个层次生物大分子为目标 ,基因药物的研究主要针对致病基因的DNA和基因转录本mRNA两类生物大分子 .mRNA从结构上考虑是研发核酸药物的最理想靶标和策略之一 .反义寡核苷酸、特异水解基因mRNA的核酸酶(ribozyme和DNAzyme)以及具有干扰作用的双链RNA(siRNA)是药物设计的策略之二 .mRNA结构靶点研究是研发反mRNA基因药物的基础 ,mRNA分子具有高度折叠的二级及三级结构 ,阐明其可及性位点 ,筛选其结构靶位点序列是关键 .近年研究报道的靶点筛选有约 7种mRNA的实测新技术 ,以及计算机辅助软件预测分析 .但发展分子生物学实验新技术以分析、确认靶点是药物研发策略之三 .     

Target site selection for an RNA-cleaving catalytic DNA.

A small catalytic DNA, known as the 10-23 DNA enzyme or deoxyribozyme, has been shown to efficiently hydrolyze RNA at purine-pyrimidine (R-Y) junctions in vitro. Although these potentially cleavable junctions are ubiquitous, they are often protected from deoxyribozyme activity by RNA secondary structure. We have developed a multiplex cleavage assay for screening the entire length of a target RNA molecule for deoxyribozyme cleavage sites that are efficient, both in terms of kinetics and accessibility. This strategy allowed us to simultaneously compare the RNA cleaving activity of 80 deoxyribozymes for a model target gene (HPV16 E6), and an additional 60 deoxyribozymes against the rat c-myc target. The human papilloma virus (HPV) target was used primarily to characterize the multiplex system and determine its validity. The c-myc target, coupled with a smooth muscle cell proliferation assay, allowed us to assess the relationship between in vitro cleavage efficiency and c-myc gene suppression in cell culture. The multiplex reaction approach streamlines the process of revealing effective deoxyribozymes in a functional assay and provides accessibility data that may also be applicable to site selection for other hybridization-based agents.